YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity.

enteric bacteria glycosyltransferase type three secretion system effectors

Journal

Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317

Informations de publication

Date de publication:
23 Feb 2021
Historique:
received: 12 01 2021
revised: 10 02 2021
accepted: 21 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 7 3 2021
Statut: epublish

Résumé

The type III secretion system effector proteins NleB and SseK are glycosyltransferases that glycosylate protein substrates on arginine residues. We conducted high-throughput screening assays on 42,498 compounds to identify NleB/SseK inhibitors. Such small molecules may be useful as mechanistic probes and may have utility in the eventual development of anti-virulence therapies against enteric bacterial pathogens. We observed that YM155 (sepantronium bromide) inhibits the activity of

Identifiants

pubmed: 33672424
pii: pathogens10020253
doi: 10.3390/pathogens10020253
pmc: PMC7926936
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : P20GM113117
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM113117
Pays : United States
Organisme : NIH HHS
ID : P20GM130448
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103638
Pays : United States
Organisme : NIH HHS
ID : P20GM103638
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI153202
Pays : United States
Organisme : CMLD Legacy
ID : GM111385
Organisme : NIH HHS
ID : AI153202
Pays : United States

Références

Front Cell Infect Microbiol. 2018 Dec 18;8:435
pubmed: 30619781
Infect Immun. 2018 Feb 20;86(3):
pubmed: 29311233
Nat Commun. 2018 Oct 16;9(1):4283
pubmed: 30327479
Arch Biochem Biophys. 2001 Feb 1;386(1):25-9
pubmed: 11360997
Nature. 2013 Sep 12;501(7466):242-6
pubmed: 23955153
Can J Cardiol. 2004 Oct;20 Suppl C:11C-16C
pubmed: 16807618
Molecules. 2018 Aug 06;23(8):
pubmed: 30082668
J Biol Chem. 1993 Oct 25;268(30):22463-8
pubmed: 8226754
Curr Top Microbiol Immunol. 2018;416:117-148
pubmed: 30062592
J Biol Chem. 2018 Apr 6;293(14):5064-5078
pubmed: 29449376
Cancer Res. 2007 Sep 1;67(17):8014-21
pubmed: 17804712
Pharm Res. 1986 Oct;3(5):298-301
pubmed: 24271714
Cell Host Microbe. 2013 Jan 16;13(1):87-99
pubmed: 23332158
Cells. 2019 Oct 17;8(10):
pubmed: 31627336
Nature. 2013 Sep 12;501(7466):247-51
pubmed: 24025841
Clin Microbiol Rev. 2004 Oct;17(4):926-41, table of contents
pubmed: 15489355
Biochim Biophys Acta. 2012 Nov;1823(11):2057-68
pubmed: 22565157
Medchemcomm. 2019 Jan 29;10(5):712-716
pubmed: 31191861
Cancer Sci. 2011 Mar;102(3):614-21
pubmed: 21205082
Mutat Res. 1998 Jun 5;401(1-2):55-63
pubmed: 9639674
Expert Opin Investig Drugs. 2005 Apr;14(4):511-9
pubmed: 15882124
J Biol Chem. 2017 Jul 7;292(27):11423-11430
pubmed: 28522607
Anticancer Drugs. 2017 Feb;28(2):142-152
pubmed: 27754993
Nat Med. 1997 Aug;3(8):917-21
pubmed: 9256286

Auteurs

Congrui Zhu (C)

College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.

Samir El Qaidi (S)

College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.

Peter McDonald (P)

HTS Laboratory, University of Kansas, Lawrence, KS 66047, USA.

Anuradha Roy (A)

HTS Laboratory, University of Kansas, Lawrence, KS 66047, USA.

Philip R Hardwidge (PR)

College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.

Classifications MeSH